- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18)
43 result(s) found for: Silver.
Displaying page 1 of 3.
EudraCT Number: 2011-003309-12 | Sponsor Protocol Number: P100129 | Start Date*: 2011-11-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005300-15 | Sponsor Protocol Number: 201201 | Start Date*: 2012-03-27 |
Sponsor Name:University Hospital Hvidovre | ||
Full Title: Treatment of Granuloma Umbilical in newborn babies - comparison of treatment with Silver Nitrate versus alcohol swaps versus steroid creme group IV. | ||
Medical condition: Granuloma Umbilical | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000494-22 | Sponsor Protocol Number: 2004/120 | Start Date*: 2005-07-12 |
Sponsor Name:Department of Obstetrics and Gynecolog, Randers Centralsygehusy | ||
Full Title: Ny behandling af bartholins cyste/abscess med sølvnitrat | ||
Medical condition: Bartholins cyste/abscess | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002571-14 | Sponsor Protocol Number: DFU06/0001 | Start Date*: 2007-06-21 |
Sponsor Name:The University of Manchester [...] | ||
Full Title: The Potential use of Larval Therapy/Biogun and Silver to Reduce Colonisation of MRSA in Diabetic Foot Ulcers. | ||
Medical condition: Methicillin Resistant Staphylococcus Aureus (MRSA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-006089-32 | Sponsor Protocol Number: 05/EN/03 | Start Date*: 2006-05-04 |
Sponsor Name:NHS Greater Glasgow - Yorkhill Division | ||
Full Title: A prospective randomised controlled trial of management of recurrent nosebleeds in children: antiseptic cream alone versus antiseptic cream with nasal cautery | ||
Medical condition: Recurrent Paediatric Epistaxis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005442-23 | Sponsor Protocol Number: 411-LY-08-01-0000 | Start Date*: 2009-02-19 | ||||||||||||||||
Sponsor Name:Leyh Pharma GmbH | ||||||||||||||||||
Full Title: Evaluation of the efficacy and safety of nose spray containing 3% silver protein diacetyl tannate (SEAT) in patients with uncomplicated viral rhinitis. A placebo-controlled, randomized, multicentri... | ||||||||||||||||||
Medical condition: treatment of uncomplicated rhinal infections | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005054-46 | Sponsor Protocol Number: D1448C00011 | Start Date*: 2006-03-17 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR... | ||
Medical condition: Generalised Anxiety Disorder (GAD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) ES (Completed) DK (Completed) DE (Completed) SK (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001251-37 | Sponsor Protocol Number: 2011-011 | Start Date*: 2011-04-20 | |||||||||||
Sponsor Name:Vu Medical center | |||||||||||||
Full Title: Exploring alternative wound care treatment for percutanous gastrostomy site infection: a prospective, randomized, open, blinded end-point (PROBE) design. | |||||||||||||
Medical condition: Infection of the PEG(percutanous endoscopic gastrostomy)-insertion site. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005037-39 | Sponsor Protocol Number: KEKLUKACS-CLIN-01 | Start Date*: 2012-04-17 |
Sponsor Name:Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság | ||
Full Title: A Phase II Randomized, Controlled Parallel-Group Pilot Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulphadiazine (Dermazin®, SSD) Therapy in the Wound... | ||
Medical condition: Patients with burn injuries confined to the trunk and/or upper and lower extremities. Total burn area for all burns on a single patient should be no greater than 15% of TBSA. Patients’ total study ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005124-42 | Sponsor Protocol Number: KEKLUKACS-CLIN-02 | Start Date*: 2014-03-17 |
Sponsor Name:Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság | ||
Full Title: A Phase II/III Adaptive, Seamless, Prospective, Randomized, Controlled, Parallel, Open Multicenter Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulfadi... | ||
Medical condition: Partial thickness (second-degree) burns. Total study target burn area: > 25 cm2 < 400 cm2 (or 2% of TBSA), and the burn therapy begun within 6-72 hours. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003867-76 | Sponsor Protocol Number: RRK4249 | Start Date*: 2013-11-07 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: A prospective, randomised controlled trial to determine the safety and efficacy of steroid impregnated tape compared to standard therapy with silver nitrate in the treatment of over-granulating per... | |||||||||||||||||||||||||||||||||
Medical condition: Over-granulation of peritoneal dialysis exit site in patients with End Stage Renal Failure | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005362-36 | Sponsor Protocol Number: SiLVER 05 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:Regensburg University Hospital | |||||||||||||
Full Title: A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Prophylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) BE (Completed) NO (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005019-96 | Sponsor Protocol Number: 20101221 | Start Date*: 2014-09-11 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) | |||||||||||||
Medical condition: Immune Thrombocytopenia (ITP) in Paediatric Subjects | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) GB (Completed) HU (Completed) Outside EU/EEA PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005300-29 | Sponsor Protocol Number: SDF1 | Start Date*: 2016-06-06 |
Sponsor Name:Malmö University, Faculty of Odontology | ||
Full Title: Prevention and treatment of initial rotcaries among elderly in Skåne. | ||
Medical condition: Dental caries | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000714-65 | Sponsor Protocol Number: PHAGOBURN | Start Date*: 2015-06-24 |
Sponsor Name:Pherecydes Pharma SA | ||
Full Title: Evaluation of phage therapy for the treatment of Pseudomonas aeruginosa wound infections in burned patients (Phase I-II clinical trial) | ||
Medical condition: P. aeruginosa infected wound in burned patients. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004347-10 | Sponsor Protocol Number: 20080009 | Start Date*: 2009-06-17 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Im... | |||||||||||||
Medical condition: Thrombocytopenia associated with ITP | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) PL (Completed) BE (Completed) ES (Completed) HU (Completed) SE (Completed) EE (Completed) IT (Completed) LT (Completed) SI (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000530-37 | Sponsor Protocol Number: 24978 | Start Date*: 2004-09-16 | |||||||||||
Sponsor Name:Serono International S.A. | |||||||||||||
Full Title: A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjec... | |||||||||||||
Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000837-17 | Sponsor Protocol Number: NL80854.018.22 | Start Date*: 2022-12-07 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study | ||
Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006833-29 | Sponsor Protocol Number: BPS-MR-PAH-202Amendment1Ireland | Start Date*: 2009-06-29 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001966-39 | Sponsor Protocol Number: CBYL719C2303 | Start Date*: 2021-09-27 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advan... | |||||||||||||
Medical condition: Hormone receptor positive, HER2-negative advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
